PERCEPTIVE ADVISORS LLC
Q3 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001224962
· CRD 154703
· SEC-registered investment adviser
$5.7B Reported Value Total
PERCEPTIVE ADVISORS reports 26 total accounts under management (AUM). There are 26 discretionary accounts valued at $11,765,315,630, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
29 funds
· $11.7B gross asset value
Hedge Fund: $10.5B · Venture Capital Fund: $713.7M · Private Equity Fund: $480.2M · Other: $14.7M
Source: Form ADV filed 2026-07-13
Reported value
$5.7B
Quarter over quarter
—
Holdings
—
Top-10 concentration
—
Key People
Form ADV owners & control persons
Joseph Eric Edelman
CHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER
Adam Leo Stone
CHIEF INVESTMENT OFFICER
Shmuel Mordechai Cohn
CHIEF FINANCIAL OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $5.7B |
| Positions | 99 |
| Change in reported value | -13.8% |
| New positions | 23 |
| Exited positions | 25 |
| Position turnover | 38.7% |
| Top-10 concentration | 49.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
99 | $5.7B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
101 | $6.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
91 | $5.1B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
111 | $5.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
90 | $3.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
82 | $2.7B |
|
Q1 2025 13F
Filed May 15, 2025
|
86 | $2.8B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
97 | $3.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
102 | $4.7B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
107 | $4.2B |
|
Q1 2024 13F
Filed May 15, 2024
|
105 | $5.7B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
97 | $4.5B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
87 | $3.0B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
88 | $3.5B |
|
Q1 2023 13F
Filed May 15, 2023
|
98 | $3.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
94 | $3.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
113 | $3.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
107 | $3.2B |
|
Q1 2022 13F
Filed May 16, 2022
|
131 | $5.0B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
140 | $6.5B |
34 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PRAX PRAXIS PRECISION MEDICINES I | $589.7M | 10.27% |
| 2 | AMLX AMYLYX PHARMACEUTICALS INC | $307.7M | 5.36% |
| 3 | SYRE SPYRE THERAPEUTICS INC | $292.1M | 5.09% |
| 4 | MRNA P MODERNA INC | $269.6M | 4.7% |
| 5 | CELC CELCUITY INC | $252.9M | 4.4% |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | $241.1M | 4.2% |
| 7 | ROIV ROIVANT SCIENCES LTD | $238.1M | 4.15% |
| 8 | RLAY RELAY THERAPEUTICS INC | $229.8M | 4.0% |
| 9 | ASND ASCENDIS PHARMA A/S | $221.3M | 3.86% |
| 10 | TVTX TRAVERE THERAPEUTICS INC | $208.6M | 3.63% |
| 11 | FRNM FREENOME INC | $198.5M | 3.46% |
| 12 | EWTX EDGEWISE THERAPEUTICS INC | $168.0M | 2.93% |
| 13 | INBX INHIBRX BIOSCIENCES INC | $129.3M | 2.25% |
| 14 | NRIX NURIX THERAPEUTICS INC | $127.4M | 2.22% |
| 15 | KARD KARDIGAN INC | $121.0M | 2.11% |
| 16 | MGTX MEIRAGTX HLDGS PLC | $118.7M | 2.07% |
| 17 | PTGX PROTAGONIST THERAPEUTICS INC | $117.9M | 2.05% |
| 18 | IMTX IMMATICS N.V | $98.7M | 1.72% |
| 19 | ZYME ZYMEWORKS INC | $93.9M | 1.64% |
| 20 | ORKA ORUKA THERAPEUTICS INC | $89.3M | 1.56% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.